EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
Crispr cans a next-gen project
The CD70-targeting CTX131 heads for the scrapheap.
Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
SITC 2025 – fresh hope for Summit's Harmoni
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
An ozekibart reminder about liver toxicity
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
One of Adcetris’s twin sons strikes out
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Amgen's $1.9bn looks buried
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
